Welcome to
Clarion Clinics

Clarion Clinics was founded in 2023 by three of Australia’s leading psychedelic-assisted therapy researchers and clinicians, following their extensive experience in the leadership of clinical trials of this new treatment.

We have developed programs that aim to deliver safe and effective outcomes for people suffering with mental ill-health through the use of new treatments. Our focus is on individually-tailored and extended models of care for treatment-resistant depression and post-traumatic stress disorder.

We integrate the latest clinical research in this field with time-honoured approaches to compassionate and robust therapy to deliver the leading-edge in mental health treatment. Our goal is to provide highly supportive and transformative experiences alongside tools and practices that promote lasting positive change

New Treatments

At Clarion Clinics, we know that lasting change takes courage, compassion, and commitment.

Engaging the Clarion team means setting out on a transformative therapeutic journey that spans approximately nine months. If you’re eligible, we will accompany you closely through a tailored and extended model of care, supported by a multidisciplinary team of highly qualified, skilled, and experienced clinicians.

Our new treatments are not a standalone pharmaceutical treatment, nor are they microdosing, but instead is a specialised and comprehensive therapeutic approach.

At Clarion, our aim is to deliver the best possible outcomes through a comprehensive patient-centric approach. By drawing on our clinical team’s unparalleled experience, gleaned through working within nation-leading research trials, we’re uniquely positioned to provide these new treatments that have the potential to go far beyond anything previously available.

Express Interest in treatment

About The Treatment

A number of clinical trials have shown that these new treatments can be effective for a proportion of people with difficult-to-treat mental health conditions like post-traumatic stress disorder and treatment-resistant depression. Of the individuals who undergo this class of treatments in clinical trials, many report sustained improvements in negative symptoms, quality of life, and wellbeing.

The therapeutic effects of the new treatments can be attributed to the combination of two important factors:

  • Experiences that occasion profound insights, increased self-awareness, compassion, and shifts in perspective, among other changes.
  • Specialised therapy designed to prepare for, support, and integrate those experiences in the safest and most useful way.

The safety of our clients is our top priority. The substances we use in our treatment protocols have been shown to have good physical and psychological safety when used in supervised settings under the support of clinicians with specialised training.  

Our dedicated team of therapists and medical professionals have nation-leading experience in the safe delivery of these new treatments, and are committed to supporting each individual on their unique journey to improved functioning, quality of life, and wellbeing.

The Clarion Clinics treatment programs for post-traumatic stress disorder and treatment-resistant depression last approximately nine months. The process includes initial psychiatric and medical assessments, followed by a prolonged course of regular individual therapy, augmented by two full-day dosing sessions.

Access and affordability are important to us at Clarion Clinics, though never at the expense of safety and effectiveness. Our primary aim is to provide the best chance of sustained mental health improvements for all our clients. Our approach is to design a best-in-class service that is costed fairly, while working with clients to secure reimbursement where possible through insurance, membership organisations, or employers. Additionally, we are establishing a Health Economics Unit that will collect and analyse our real-world cost-effectiveness data towards potential Medicare reimbursement in future. We will also offer a limited number of subsidised packages within Clarion, based on financial need and suitability.

Clarion’s Melbourne clinic is now open for treatment. For new clients wishing to commence the screening process to assess eligibility for this treatment, please complete the request for further information form on this website.

The cost of treatment is as follows: 

  • Eligibility screening: pre-screening, psychiatric assessment, medical assessment, and psychological assessment – $0 (bulk billed, with no out-of-pocket costs to clients). 
  • Full treatment package: approximately 9-months of ongoing treatment, including psychiatry, psychotherapy, medicines, and aftercare – $24,000 (maximum, with possibly reductions through Medicare). 

There are potentially several Medicare refundable items within our treatment program. The exact amount which is refundable to our clients is dependent upon individual circumstances, but could be up to approximately $6,000. Our clinic practice manager will discuss your circumstances with you and calculate the amount which you can expect to be refunded by Medicare following eligibility screening. 

There is also the potential, depending upon individual circumstances, to have treatment funded through various organisations like: Department of Veterans Affairs, National Disability Insurance Scheme, WorkCover and others. We will work with you to understand whether you are eligible for any of the above funding.

Some private health insurers may also fund a portion of the fee. This is dependent upon your insurer and the type of policy you hold. Please liaise directly with your insurer, and our practice can assist in this process. 

To be eligible for treatment at Clarion Clinics, you must be diagnosed by a psychiatrist with either:

  • Treatment-resistant depression* or
  • Post-traumatic stress disorder

This diagnosis can occur through your own psychiatrist or through a psychiatrist within the Clarion team. Following confirmation of this diagnosis, you will need to undergo a medical examination and a psychological assessment to determine your suitability for this type of treatment. *Treatment Resistant Depression entails a Major Depression Disorder diagnosis that has not responded adequately to at least two forms of treatment.

There are several pathways into treatment; you can come to us directly or be referred by your psychiatrist, psychologist, or GP.
Initially, the best step is to express interest by completing the request for “Express Interest in Treatment” form on this website and we will provide you with more information regarding our services.

Express Interest in treatment

Our Core Priorities

  • Safe and effective outcomes that promote lasting positive change for our clients through innovative, tailored, and extended care.
  • Highly qualified and trained clinical staff working within evidenceinformed protocols in a supportive environment.
  • Clinical evaluation, accountability, and adaptation.
  • Improved affordability though economic evaluation, subsidies, and promoting reimbursement.
Express Interest in treatment

Who are We?

At the heart of Clarion Clinics is a collaborative effort between leading psychedelic-assisted therapy clinicians and scientists, and Incannex Healthcare (IXHL), a bio-pharmaceutical company listed on the NASDAQ.

Our clinical founders – Dr. Paul Liknaitzky, Prof. Suresh Sundram, and Sean O’Carroll – represent a respected collective within Australia’s psychedelic-assisted therapy research community. Alongside the wider clinical and research team, their in-depth experience developing and delivering these new treatments contributes to Clarion’s distinct identity, positioning us at the forefront of this field.

Working closely with IHL, our founders have participated in multiple world-first clinical trials of psychedelic-assisted therapy at Monash University over the past years. By bringing together clinical proficiency, innovative and rigorous science, and a commitment to client-centric care, we endeavour to set the benchmark for best-practice in this new treatment field here in Australia.

Our Team